Clinical Trial: NCT04891068
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | University of Illinois at Chicago |
| Information Provided By: | University of Illinois at Chicago |
| Last Update Posted: | 2026-06-23 |
Study Overview
Brief Summary
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.
Official Title
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Conditions
Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
Intervention / Treatment
- Drug: Azacitidine
Other Study ID Numbers
- 2021-0215
Start Date (Actual)
2022-01-10
Primary Completion Date (Estimated)
2027-05
Study Completion Date (Estimated)
2027-05
Enrollment (Estimated)
40
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | University of Illinois at Chicago |
| Information Provided By: | University of Illinois at Chicago |
| Last Update Posted: | 2026-06-23 |
Study Overview
Brief Summary
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.
Official Title
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Conditions
Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
Intervention / Treatment
- Drug: Azacitidine
Other Study ID Numbers
- 2021-0215
Start Date (Actual)
2022-01-10
Primary Completion Date (Estimated)
2027-05
Study Completion Date (Estimated)
2027-05
Enrollment (Estimated)
40
Study Type
Interventional
Phase
Phase 2